Ornidazole solution
Ornidazole solution is mainly composed of Ornidazole (HY-B0508). Ornidazole (Ro 7-0207) is a nitroimidazole derivative with anti-trichomonad activity and in vitro activity against a variety of anaerobic bacteria. Ornidazole inhibits Sonic hedgehog (Shh) signaling pathway, exhibits antitumor activity. Ornidazole can be used in research of Crohn’s disease.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 16773-42-5
- 화학식: C7H10ClN3O3
- 분자량:219.63
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
Chemical Information
-
CAS No. 16773-42-5
-
분자량 219.63
-
화학식 C7H10ClN3O3
-
SMILES
CC1=NC=C(N1CC(O)CCl)[N+]([O-])=O
-
Synonyms
Ro 7-0207 solution
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Anaerobic Bacterial Culture
Anaerobic bacterial culture detects viable bacteria that can grow under oxygen-depleted conditions; the readout is visible colony formation or broth turbidity after incubation in a chamber, jar, pouch, bag, or roll-tube system that maintains anaerobiosis. Oxygen control is central to the method because recovery depends on limiting oxygen exposure during collection, transport, inoculation, and incubation.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
순도&문서
References
[1]. Rutgeerts, P., et al., Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology, 2005. 128(4): p. 856-61. [Content Brief]
[2]. Goldstein, E.J., V.L. Sutter, and S.M. Finegold, Comparative susceptibilities of anaerobic bacteria to metronidazole, ornidazole, and SC-28538. Antimicrob Agents Chemother, 1978. 14(4): p. 609-13. [Content Brief]
[3]. Evyapan G, et al., Ornidazole suppresses CD133+ melanoma stem cells via inhibiting hedgehog signaling pathway and inducing multiple death pathways in a mouse model. Croat Med J. 2022 Oct 31;63(5):461-474. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)